Neurocrine Biosciences Inc (NBIX)

Add to Watchlists
Create an Alert
Quickflows
115.00 +3.92  +3.53% NASDAQ Jan 21, 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All NBIX News

News

View All Events

Events

Date Type Description
02/04/2021 Earnings Neurocrine Biosciences Inc Fourth Quarter Earnings for 2020 Release
02/04/2021 16:30 EST Misc Neurocrine Biosciences Inc Fourth Quarter Earnings Conference Call for 2020
11/09/2020 Earnings Neurocrine Biosciences Inc Third Quarter Earnings Result for 2020
11/09/2020 16:30 EST Misc Neurocrine Biosciences Inc Third Quarter Earnings Conference Call for 2020
08/03/2020 16:30 EDT Misc Neurocrine Biosciences Inc Second Quarter Earnings Conference Call for 2020
08/03/2020 Earnings Neurocrine Biosciences Inc Second Quarter Earnings Result for 2020
05/19/2020 Misc Neurocrine Biosciences Inc Annual General Meeting for 2019
05/06/2020 16:30 EDT Misc Neurocrine Biosciences Inc First Quarter Earnings Conference Call for 2020
05/06/2020 Earnings Neurocrine Biosciences Inc First Quarter Earnings Result for 2020
02/07/2020 Misc Neurocrine Biosciences Inc Annual Report for 2019
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 1.042B
Total Expenses (TTM) 701.43M
Net Income (TTM) 93.41M

Balance Sheet View Statement

Total Assets (Quarterly) 1.503B
Total Liabilities (Quarterly) 698.30M
Shareholders Equity (Quarterly) 804.30M

Cash Flow Statement View Statement

Cash from Operations (TTM) 242.15M
Cash from Investing (TTM) -14.37M
Cash from Financing (TTM) 28.91M

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.neurocrine.com
  • Investor Relations URL: http://phoenix.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-news&nyo=0
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Feb. 04, 2021
  • Last Earnings Release: Nov. 09, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: Dec. 29, 1995
  • Description: Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 115.00
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
FBT First Trust NYSE Arca Biotech ETF 3.31%
DYN1628 Dynamic Power American Growth Series IP (USD) 2.98%
FIJYX Fidelity Advisor® Biotechnology Z 2.70%
BBP Virtus LifeSci Biotech Products ETF 2.26%
BBH VanEck Vectors Biotech ETF 2.10%
ETCHX Eventide Healthcare & Life Sciences C 1.98%
JFNSX Janus Henderson Global Life Sciences S 1.73%
GTMRX Goldman Sachs Small/Mid Cap Growth R 1.54%
XBI SPDR® S&P Biotech ETF 1.02%
FBIOX Fidelity® Select Biotechnology 0.99%
IBB iShares Nasdaq Biotechnology ETF 0.79%
LABU Direxion Daily S&P Biotech Bull 3X ETF 0.35%

Comparables

Edit
INO Inovio Pharmaceuticals Inc
DNLI Denali Therapeutics Inc
CVM CEL-SCI Corp
AIM AIM ImmunoTech Inc
LCTX Lineage Cell Therapeutics Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.